Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHY

30 Mar 2023

Abstract excerpt

PURPOSE: To evaluate available rationale and outcomes of randomized trial results for complement inhibition for geographic atrophy. METHODS: Data from recently completed randomized trials of complement inhibition, particularly for pegcetacoplan and avacincaptad pegol, were evaluated for both the outcome, area of autofluorescence loss, and functional vision tests. RESULTS: Pegcetacoplan 2 mg showed statistically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Sclerosis Research Studies
Share to Ophthalmology and Visual Impairment Studies
Share to Retinal Diseases and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36996460
DOI: 10.1097/iae.0000000000003796

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHYPMID 36996460Read ↗

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular DegenerationSemantic proximity Read ↗

Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad PegolSemantic proximity Read ↗

Treating patients with geographic atrophy: are we there yet?Semantic proximity Read ↗

Local Complement Inhibition for Geographic Atrophy in Age-Related Macular Degeneration: Prospects, Challenges, and Unanswered QuestionsSemantic proximity Read ↗

The roadmap to geographic atrophy treatment: A journey of trials and promiseSemantic proximity Read ↗

Complement cascade inhibition in geographic atrophy: a review.Semantic proximity Read ↗

Informing Endpoints for Clinical Trials of Geographic AtrophySemantic proximity Read ↗

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.Semantic proximity Read ↗

Complement system modulation in age-related macular degeneration: navigating failures, building future successesSemantic proximity Read ↗

Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degenerationSemantic proximity Read ↗

Therapeutic targeting of the complement system in ocular diseaseSemantic proximity Read ↗

C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.